Uncategorized

Pfizer drug acquired in Seagen deal disappoints in lung cancer study

Published

on

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version